As relapses in MLL-rearranged ALL patients often occur early during treatment [1,2], suggesting that small subsets of leukemic cells evade therapy [24], we studied whether the observed ablation of leukemia by irinotecan would be maintained after cessation of irinotecan treatment. This evidence concerns the gene KMT2A and acute lymphoblastic leukemia.